TY  - JOUR
  - O'Connell, J.,Houston, A.,Bennett, M. W.,O'Sullivan, G. C.,Shanahan, F.
  - 2001
  - March
  - Nat Mednat Med
  - Immune privilege or inflammation? Insights into the Fas ligand enigma
  - Validated
  - ()
  - 7
  - 33
  - 271
  - 4
  - Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
  - 1078-8956 (Print) 1078-89
DA  - 2001/03
ER  - 

@article{V280546722,
   = {O'Connell,  J. and Houston,  A. and Bennett,  M. W. and O'Sullivan,  G. C. and Shanahan,  F. },
   = {2001},
   = {March},
   = {Nat Mednat Med},
   = {Immune privilege or inflammation? Insights into the Fas ligand enigma},
   = {Validated},
   = {()},
   = {7},
   = {33},
  pages = {271--4},
   = {{Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.}},
  issn = {1078-8956 (Print) 1078-89},
  source = {IRIS}
}